• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Quinic acids and derivatives

Recent Advances in the Study of 5-Galloylquinic Acid (53584-43-3): A Comprehensive Research Brief

5-Galloylquinic acid (CAS: 53584-43-3) is a naturally occurring polyphenolic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its diverse biological activities. Recent studies have explored its potential therapeutic applications, including antioxidant, anti-inflammatory, and anticancer properties. This research brief aims to synthesize the latest findings on 5-Galloylquinic acid, providing a comprehensive overview of its mechanisms of action, pharmacological effects, and potential clinical applications.

One of the most notable advancements in the study of 5-Galloylquinic acid is its role in modulating oxidative stress. A 2023 study published in the Journal of Agricultural and Food Chemistry demonstrated that 5-Galloylquinic acid exhibits potent antioxidant activity by scavenging free radicals and enhancing the activity of endogenous antioxidant enzymes. The study utilized in vitro models to show that the compound significantly reduces lipid peroxidation and DNA damage, suggesting its potential as a therapeutic agent for oxidative stress-related diseases such as neurodegenerative disorders and cardiovascular diseases.

In addition to its antioxidant properties, 5-Galloylquinic acid has been investigated for its anti-inflammatory effects. A recent preclinical study published in Phytomedicine revealed that the compound inhibits the production of pro-inflammatory cytokines, such as TNF-α and IL-6, by suppressing the NF-κB signaling pathway. These findings highlight its potential as a natural alternative to conventional anti-inflammatory drugs, with fewer side effects. The study also noted that 5-Galloylquinic acid could be a promising candidate for the treatment of chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the anticancer potential of 5-Galloylquinic acid. A 2022 study in Molecular Cancer Therapeutics reported that the compound induces apoptosis in various cancer cell lines, including breast and colon cancer, by activating the intrinsic apoptotic pathway. The researchers identified that 5-Galloylquinic acid upregulates pro-apoptotic proteins such as Bax and downregulates anti-apoptotic proteins like Bcl-2. These results suggest that the compound could be developed as an adjunct therapy for cancer treatment, particularly in combination with existing chemotherapeutic agents to enhance efficacy and reduce toxicity.

Despite these promising findings, challenges remain in the clinical translation of 5-Galloylquinic acid. Issues such as bioavailability, stability, and formulation need to be addressed to fully harness its therapeutic potential. Recent research has focused on improving the delivery of 5-Galloylquinic acid using nanotechnology-based approaches. For instance, a 2023 study in the International Journal of Pharmaceutics developed a liposomal formulation of 5-Galloylquinic acid, which significantly improved its solubility and bioavailability in animal models. Such advancements are critical for the future development of 5-Galloylquinic acid-based therapeutics.

In conclusion, 5-Galloylquinic acid (53584-43-3) represents a promising bioactive compound with multifaceted pharmacological properties. Recent studies have elucidated its mechanisms of action and potential therapeutic applications, paving the way for further research and development. Future studies should focus on overcoming the current limitations and exploring its clinical efficacy in human trials. The integration of advanced delivery systems and combination therapies may further enhance the therapeutic potential of this compound, making it a valuable asset in the field of chemical biology and medicine.

• 17365-11-6(Theogallin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)